Who to watch in hot pharma space

Posted 30 June 2025 PM

As major pharmas muscle their way into the burgeoning radioligand therapy market through high-stakes acquisitions, a number of smaller companies are working on progressing the technology. 

For the next few years Novartis' radioligand Pluvicto is predicted to dominate the radiopharmaceutical industry, which Clarivate projects will exceed $20 billion (US$13 billion) over the next decade across all forms of radiopharmaceuticals. Its report Radioligand Innovators Ushering in a New Era of Precision Oncology: Companies to Watch 2025 lists six companies expected to play a significant part in the industry.

To see the whole article, please login